Publication: Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing Klebsiella pneumoniae.
No Thumbnail Available
Identifiers
Date
2016-07-26
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Export
Abstract
Invasive infections caused by KPC-producing Klebsiella pneumoniae (KPCKP) are associated with very high mortality. Because infection is usually preceded by rectal colonization, we investigated if decolonization therapy (DT) with aminoglycosides had a protective effect in selected patients. Patients with rectal colonization by colistin-resistant KPCKP who were at high risk of developing infection (because of neutropenia, surgery, previous recurrent KPCKP infections or multiple comorbidities) were followed for 180 days. Cox regression analysis including a propensity score was used to investigate the impact of the use of two intestinal decolonization regimens with oral aminoglycosides (gentamicin and neomycin/streptomycin) on mortality, risk of KPCKP infections and microbiological success. The study was registered with ClinicalTrials.gov (NCT02604849). The study sample comprised 77 colonized patients, of which 44 (57.1%) received DT. At 180 days of follow-up, decolonization was associated with a lower risk of mortality in multivariate analyses (HR 0.18; 95% CI 0.06-0.55) and a lower risk of KPCKP infections (HR 0.14; 95% CI 0.02-0.83) and increased microbiological success (HR 4.06; 95% CI 1.06-15.6). Specifically, gentamicin oral therapy was associated with a lower risk of crude mortality (HR 0.15; 95% CI 0.04-0.54), a lower risk of KPCKP infections (HR 0.86; 95% CI 0.008-0.94) and increased microbiological response at 180 days of follow-up (HR 5.67; 95% CI 1.33-24.1). Neomycin/streptomycin therapy was only associated with a lower risk of crude mortality (HR 0.22; 95% CI 0.06-0.9). Intestinal decolonization with aminoglycosides is associated with a reduction in crude mortality and KPCKP infections at 180 days after initiating treatment.
Description
MeSH Terms
Administration, Oral
Aged
Aged, 80 and over
Aminoglycosides
Anti-Bacterial Agents
Carrier State
Colistin
Decontamination
Drug Resistance, Bacterial
Female
Follow-Up Studies
Humans
Klebsiella Infections
Klebsiella pneumoniae
Male
Middle Aged
Risk Assessment
Survival Analysis
Treatment Outcome
beta-Lactamases
Aged
Aged, 80 and over
Aminoglycosides
Anti-Bacterial Agents
Carrier State
Colistin
Decontamination
Drug Resistance, Bacterial
Female
Follow-Up Studies
Humans
Klebsiella Infections
Klebsiella pneumoniae
Male
Middle Aged
Risk Assessment
Survival Analysis
Treatment Outcome
beta-Lactamases